BSE Live
Mar 27, 16:01Prev. Close
78.68
Open Price
77.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:54Prev. Close
78.59
Open Price
77.40
Bid Price (Qty.)
77.95 (161)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of IOL Chemicals and Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 3.44 | 23.07 | 23.84 | 28.22 | 76.21 | |
| Diluted EPS (Rs.) | 3.44 | 23.07 | 23.84 | 28.22 | 76.21 | |
| Cash EPS (Rs.) | 5.89 | 33.77 | 31.70 | 35.59 | 82.35 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 57.48 | 274.46 | 256.61 | 236.80 | 214.69 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 57.48 | 274.46 | 256.61 | 236.80 | 214.69 | |
| Dividend / Share(Rs.) | 0.80 | 5.00 | 4.00 | 4.00 | 6.00 | |
| Revenue from Operations/Share (Rs.) | 70.83 | 363.28 | 377.64 | 372.00 | 335.03 | |
| PBDIT/Share (Rs.) | 7.65 | 44.56 | 42.94 | 49.11 | 104.95 | |
| PBIT/Share (Rs.) | 5.20 | 33.85 | 35.08 | 41.74 | 98.32 | |
| PBT/Share (Rs.) | 4.70 | 31.11 | 32.28 | 37.96 | 97.32 | |
| Net Profit/Share (Rs.) | 3.44 | 23.07 | 23.84 | 28.22 | 75.72 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 10.80 | 12.26 | 11.37 | 13.20 | 31.32 | |
| PBIT Margin (%) | 7.34 | 9.31 | 9.28 | 11.22 | 29.34 | |
| PBT Margin (%) | 6.63 | 8.56 | 8.54 | 10.20 | 29.04 | |
| Net Profit Margin (%) | 4.85 | 6.34 | 6.31 | 7.58 | 22.60 | |
| Return on Networth / Equity (%) | 5.98 | 8.40 | 9.29 | 11.91 | 35.27 | |
| Return on Capital Employed (%) | 8.61 | 11.80 | 13.16 | 16.93 | 43.74 | |
| Return on Assets (%) | 4.24 | 6.03 | 6.92 | 8.45 | 27.61 | |
| Total Debt/Equity (X) | 0.07 | 0.02 | 0.05 | 0.03 | 0.00 | |
| Asset Turnover Ratio (%) | 0.90 | 1.00 | 1.11 | 1.22 | 122.16 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.89 | 2.00 | 2.02 | 2.10 | 3.52 | |
| Quick Ratio (X) | 1.30 | 1.24 | 1.30 | 1.30 | 2.50 | |
| Inventory Turnover Ratio (X) | 5.29 | 3.82 | 4.18 | 4.48 | 6.66 | |
| Dividend Payout Ratio (NP) (%) | 23.24 | 21.67 | 16.78 | 21.26 | 5.28 | |
| Dividend Payout Ratio (CP) (%) | 13.57 | 14.80 | 12.62 | 16.85 | 4.85 | |
| Earnings Retention Ratio (%) | 76.76 | 78.33 | 83.22 | 78.74 | 94.72 | |
| Cash Earnings Retention Ratio (%) | 86.43 | 85.20 | 87.38 | 83.15 | 95.15 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1,705.63 | 2,012.51 | 1,719.64 | 1,982.03 | 2,867.83 | |
| EV/Net Operating Revenue (X) | 0.82 | 0.94 | 0.78 | 0.91 | 1.46 | |
| EV/EBITDA (X) | 7.60 | 7.69 | 6.82 | 6.87 | 4.65 | |
| MarketCap/Net Operating Revenue (X) | 0.86 | 1.00 | 0.75 | 0.95 | 1.64 | |
| Retention Ratios (%) | 76.75 | 78.32 | 83.21 | 78.73 | 94.71 | |
| Price/BV (X) | 1.06 | 1.32 | 1.10 | 1.49 | 2.56 | |
| Price/Net Operating Revenue | 0.86 | 1.00 | 0.75 | 0.95 | 1.64 | |
| Earnings Yield | 0.06 | 0.06 | 0.08 | 0.08 | 0.14 |
25.02.2026
IOL Chemicals Consolidated December 2025 Net Sales at Rs 580.39 crore, up 10.91% Y-o-Y
25.02.2026
IOL Chemicals Standalone December 2025 Net Sales at Rs 580.39 crore, up 10.91% Y-o-Y
08.12.2025
17.11.2025
IOL Chemicals Consolidated September 2025 Net Sales at Rs 567.53 crore, up 7.95% Y-o-Y
25.02.2026
IOL Chemicals Consolidated December 2025 Net Sales at Rs 580.39 crore, up 10.91% Y-o-Y
25.02.2026
IOL Chemicals Standalone December 2025 Net Sales at Rs 580.39 crore, up 10.91% Y-o-Y
17.11.2025
IOL Chemicals Consolidated September 2025 Net Sales at Rs 567.53 crore, up 7.95% Y-o-Y
12.11.2025
IOL Chemicals Standalone September 2025 Net Sales at Rs 567.53 crore, up 7.95% Y-o-Y
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth